Recent Finacing
Recent Raise
Novoron Bioscience develops NOVO-118, a preclinical therapeutic targeting LDL receptor-family pathways to promote axonal regeneration and remyelination for spinal cord injury, multiple sclerosis, and other indications.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Novoron Bioscience.
